Mike Paglia, CTO
SVP of CMC Operations
Michael is the Senior Vice President of CMC Operations at AlloVir and is responsible for GMP manufacturing operations and CMC regulatory strategy for the development of AlloVir’s allogeneic T – Cell therapies.
Michael has spent the last sixteen years in biotechnology building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late stage clinical trials.
Previously, Michael was the Vice President of CMC Operations at Oncorus and the program lead for the development of a next-generation oncolytic immunotherapy platform to treat cancer. The CMC Operations group at Oncorus consists of process development, manufacturing, analytical sciences, quality control and regulatory sciences responsible for the development and characterization of micro-RNA attenuated oncolytic herpes viruses. Prior to Oncorus, Michael was the Sr. Director of Technical Operations and head of Cellular Process Development and Manufacturing Operations at bluebird bio. Michael established and was responsible for internal and external cellular process development and analytics, cGMP manufacturing operations, CMC regulatory strategy, cellular procurement, and process characterization and validation activities for lentiviral vector-based autologous hematopoietic stem cell and CAR T cell programs.